Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab
- 12 January 2017
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 376 (2) , 191-192
Abstract
Inhibition of immune checkpoints with the use of antibodies targeting programmed cell death 1 (PD-1) or monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) has been used clinically in patients with various types of cancer. In the limited number of reported cases in which these antibodies have been used in patients who have undergone kidney transplantation,1 these agents have been associated with cell-mediated and antibody-mediated rejection (see Table S2 in the Supplementary Appendix, available with the full text of this letter at NEJM.org).Keywords
This publication has 5 references indexed in Scilit:
- Tumor Regression and Allograft Rejection after Administration of Anti–PD-1New England Journal of Medicine, 2016
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterJournal of Clinical Oncology, 2015
- Role of the PD-1 Pathway in the Immune ResponseAmerican Journal of Transplantation, 2012
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialThe Lancet Oncology, 2012
- Rapamycin: An anti-cancer immunosuppressant?Critical Reviews in Oncology/Hematology, 2005